This study is a prospective, single-arm, US multi-center, descriptive study to evaluate the safety of multiple access site closure in a single vein with the Perclose SMC. A total of 35 subjects will be registered at 2 US investigational sites. All subjects must have femoral DUS at discharge and at a 30-day follow-up visit (if any access site-related vascular complications (either symptomatic/visible or asymptomatic/nonvisible), nerve injury, or infection at discharge, by either the investigator or the core laboratory).
The study will evaluate the safety of multiple access site closure in a single vein with the Perclose SMC by scheduled DUS at discharge and at 30 days (if vascular complications observed at discharge) in asymptomatic or non-visible subjects.